Uncategorized

Bayer Healthcare applies for EU marketing authorisation of aflibercept for treatment of wet age-related macular degeneration

by NeLM - Ophthalmology • 2011/06/08 • 0 Comments

Source: BioSpace.com
Area: News
According to a report by BioSpace, Bayer HealthCare has submitted an application for marketing authorisation to the EMA for VEGF Trap-Eye (aflibercept) for the treatment of the neovascular form of age-related macular degeneration (wet AMD). The submission is based on positive results from two Phase 3 trials, the VIEW 1 study and the VIEW 2 study (previously reported on NeLM - please see link below).

Full Story →

← Trial Of Drug’s Impact On Neurological Disease Affecting Women

First Head-to-Head Study In Branch Retinal Vein Occlusion(BRVO) Announced In Europe And Israel →

Post navigation